Abstract

The objective of this study is to explore the drug effect of valsartan in essential hypertension. Through the analysis of the treatment of 122 patients with essential hypertension who were treated in Zhuji Second People’s Hospital from June 2022 to June 2023, the patients were divided into group A and group B, with 61 individuals in each group. The patients in group A were treated with valsartan and the patients in group B were treated with amlodipine. The medication cycle of both groups was 8 w. The blood pressure levels, renal function indicators, blood lipid changes, adverse drug reactions and drug effects of the two groups of patients before and after medication were compared. The total effective rate of medication in group A was 91.8 %, and that in group B was 80.33 % (p<0.05). After treatment, the systolic blood pressure of group A was lower than that of group B and the diastolic blood pressure was higher than that of group B (p<0.05). In terms of renal function indicators, after treatment, the serum blood urea nitrogen, creatinine and other indicators of patients in group A were lower than those in group B (p<0.05). In terms of blood lipid levels, group A’s serum triacylglycerol, total cholesterol, low-density lipoprotein cholesterol was lower than that of group B (p<0.05). There was no significant difference in adverse drug reactions between the two groups (p>0.05). Valsartan treatment, as a drug for the treatment of essential hypertension has obvious efficacy, good blood lipid lowering effect, with less adverse effects causing less damage to patients’ renal function and high drug safety, which is worthy of clinical drug promotion.